NCT06568224

Therapeutic Effect of Methalazine on 27 Cases of Suppurative Hidradenitis

Treatment for Hidradenitis Suppurativa

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 27 (actual)
• Sponsor: The First Affiliated Hospital with Nanjing Medical University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory relapsing disease involving the axillae, breast ,groin and anogenital regions. The therapies of the disease are diverse, including medication and surgery. However, responses to treatments are variable and relapse is common, with no single agent being consistently effective. Objective: To evaluate the efficacy and safety of oral mesalazine treatment for hidradenitis suppurativa . Methods: Investigators reported a series of cases of patients who received oral mesalazine(1g qid) for hidradenitis suppurativa in our institution between May 2020 and September 2023. A total of 27 patients, 22 in the mild to moderate group and 5 in the severe group, were included in this study.

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
DRUG	Mesalazine	oral mesalazine 1g qid

Timeline

• Start date: 2020-05-01
• Primary completion: 2023-09-01
• Completion: 2023-09-01
• First posted: 2024-08-23
• Last updated: 2024-09-03

Locations

1 site across 1 country: China